Neurology
-
Randomized Controlled Trial Multicenter Study
ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.
To evaluate the safety and efficacy of crenezumab in patients with mild to moderate Alzheimer disease (AD). ⋯ This study provides Class II evidence that, for people with AD, crenezumab does not significantly improve cognition or function at 18 months. The study is rated Class II because <80% of enrolled patients completed the study.
-
Randomized Controlled Trial Multicenter Study
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
To assess dose-response effects of the anti-CD20 monoclonal antibody ofatumumab on efficacy and safety outcomes in a phase 2b double-blind study of relapsing forms of multiple sclerosis (RMS). ⋯ This study provides Class I evidence that for patients with RMS, ofatumumab decreases the number of new MRI gadolinium-enhancing lesions 12 weeks after treatment initiation.